|
| The clinical effect of Astragalus Life-sustaining Decoction on patients with vascular dementia caused by ischemic stroke |
| Hits 14 Download times 1 Received:August 05, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.12.04 |
| Key Words
ischemic stroke;vascular dementia;Astragalus Life-sustaining Decoction;soluble myeloid cell trigger receptor 2;lipoprotein-associated phosphatase A2;beta amyloid 1-42 |
| Author Name | Affiliation | | YUAN Lei | Neurology Department, The Second People's Hospital of Nanyang City, Nanyang 473000, China | | TAO Luling | Neurology Department, The Second People's Hospital of Nanyang City, Nanyang 473000, China | | LU Binqi | Neurology Department, The Second People's Hospital of Nanyang City, Nanyang 473000, China | | YUAN Yan | Neurology Department, The Second People's Hospital of Nanyang City, Nanyang 473000, China |
|
| Abstract
|
| [Objective] To investigate the effects of Astragalus Life-sustaining Decoction on cognitive function，serum soluble myeloid cell triggering receptor 2（sTREM2），lipoprotein-associated phosphatase A2（Lp-PLA2） and β-amyloid 1-42（Aβ1-42） in patients with vascular dementia（VD） caused by ischemic stroke. [Methods] A total of 110 patients with VD caused by ischemic stroke admitted to our hospital from January 2020 to August 2022 were selected and divided into the control group and observation group by random number table method，with 54 cases in the observation group and 53 cases in the control group. The control group received simple conventional Western medicine treatment，and the observation group was treated with Astragalus life-sustaining Decoction based on the control group. Both groups received continuous treatment for 1 month. The clinical efficacy，TCM syndrome scores，Montreal Cognitive Assessment Scale（MoCA） scores，Simple Mental State Examination Scale（MMSE） scores，National Institutes of Health Stroke Scale（NIHSS） scores，Nagagawa Dementia Scale（HDS） scores，serum sTREM2，Lp-PLA2 and Aβ1 were compared between the two groups. The adverse reactions of patients were compared between the two groups during treatment. [Results] The comparison of clinical efficacy of VD patients between the two groups showed that the total effective rate of the observation group was 92.59%，which was significantly higher than that of the control group（77.36%）（P<0.05）. After treatment，the principal symptom score，secondary symptom score，and total score of VD patients in both groups were significantly decreased（P<0.05），and the above indexes in the observation group were significantly lower than those in the control group（P<0.05）. After treatment，MoCA scores of VD patients in both groups were significantly improved（P<0.05），and MoCA scores in the observation group were significantly higher than those in the control group（P<0.05）. After treatment，MMSE，NIHSS and HDS scores of VD patients in 2 groups were significantly improved（P<0.05），and the improvement degree of the above scores in the observation group was significantly better than that in the control group（P<0.05）. After treatment，serum sTREM2，Lp-PLA2，and Aβ1-42 levels of VD patients in 2 groups were significantly decreased（P<0.05），and the above serum indexes in the observation group were significantly lower than those in the control group（P<0.05）. The total incidence of adverse reactions in the observation group and the control group was 5.56%（3/54） and 9.43%（5/53），respectively，and there was no statistical significance between the two groups（χP>2P>=0.156，P=0.693）. [Conclusion] The clinical efficacy of Astragalus Life-sustaining Decoction in patients with VD due to ischemic stroke is precise，which can lead to significant improvement in cognitive function and serum sTREM2，Lp-PLA2，and Aβ1-42 levels without increasing the risk of medication，and it is worthwhile to popularize the use of the drug in the clinic. |
|
